Background {#Sec1}
==========

Post-cardiotomy cardiogenic shock (PCCS) occurs in 2--6 % of patients undergoing surgical revascularization or valvular surgery \[[@CR1]--[@CR4]\]. Approximately 0.5--1.5 % of patients are refractory to maximal inotropic and intra-aortic balloon pump (IABP) support \[[@CR5]\]. Post-cardiotomy cardiogenic shock occurs in perioperative cardiac surgery in patients with normal preoperative myocardial function as well as those with pre-existing impaired function \[[@CR6]\]. Refractory PCCS leads rapidly to multi-organ dysfunction and is nearly always fatal \[[@CR4], [@CR7]--[@CR9]\] without the use of advanced mechanical circulatory support (AMCS). AMCS devices such as extracorporeal membrane oxygenation (ECMO) and ventricular assist devices (VAD) have been used to salvage patients who develop refractory PCCS. Survival to hospital discharge is variable \[[@CR1]--[@CR3], [@CR5], [@CR10]--[@CR12]\] though long term survival and reasonable functional outcome can be achieved \[[@CR11], [@CR13]--[@CR15]\]. However, these devices are associated with serious complications \[[@CR1], [@CR2], [@CR11], [@CR16]--[@CR18]\] and are costly \[[@CR9], [@CR19], [@CR20]\]. The UK National Health Service's (NHS) proposal to centralise AMCS funding to a few, larger cardiothoracic units has been controversial \[[@CR15]\]. Some argue that such a move would remove this potentially, life-saving resource from those cardiothoracic surgery departments excluded from AMCS funding \[[@CR15]\]. This prompted us to assess the outcome of the use of AMCS in a non-transplant, intermediate-sized unit (annual workload approximately 900 to 1000 major cardiac surgical operations) in Edinburgh, UK.

Methods {#Sec2}
=======

We retrospectively assessed our experience with AMCS in refractory PCCS over a 20-year period. These data were collected prospectively by the Royal Infirmary of Edinburgh cardiac surgery database. Our inclusion criteria included any adult patient from April 1995 to April 2015 who had received salvage V-A ECMO or VAD for PCCS refractory to IABP and maximal inotropic support following adult cardiac surgery. We gained information regarding the patients' follow-up status from accessing the cardiology follow-up clinic letters on the TrakCare^R^ system, which captures in-patient and out-patient clinical data.

The AMCS devices utilised by our unit in duration of the study included: The Levitronix^R^ CentriMag II for ECMO and Medtronic Bio-Medicus^R^ 560 for VAD support.

Results {#Sec3}
=======

There were 18 patients who met the inclusion criteria. We excluded two patients who had had AMCS for refractory PCCS. One patient was in the paediatric age group and had been operated on prior to relocation of paediatric cardiac surgery services to the Royal Hospital for Sick Children, Glasgow in year 2000. Another patient was excluded due to the lack of recorded clarity in the database on the type of AMCS support used, any potential complications and the short and the long-term outcome of this individual. In the remaining 16 patients the age range was 34--83 years (Median 71 years).

Among the remaining 16 (89 %) patients (Table. [1](#Tab1){ref-type="table"}), there was a large male predominance of 12 (75 %). Five patients (31.25 %) had undergone re-operative cardiac surgery. One patient (6.25 %) had undergone AMCS following the repair of an ascending aortic transection after a road traffic accident. Overall, 15 patients (94 %) had received a single run of V-A ECMO of which number, 10 (67 %) had received central ECMO and 5 (33 %) had received peripheral ECMO. One patient (6 %) had VAD. The mean duration of AMCS was approximately 5.4 days (Range \< 1 day -- 33 days). The most common procedure-related complication was major haemorrhage. The incidence of major cerebrovascular accident, peripheral limb ischaemia, femoral artery pseudo-aneurysm, septic shock and renal failure requiring renal replacement therapy was 18.75 %, 12.5 %, 6.25 %, 12.5 % and 18.75 % respectively (Fig. [1](#Fig1){ref-type="fig"}). Logistic EuroSCORE ranged from 2.08 to 73.26 (mean 20.21, SD = 17).Table 1Illustrates patient characteristics, the type of mechanical circulatory support and outcomes over the 11-year study periodAge & genderCo-morbidities & logistic euroSCOREDate of surgeryOriginal operationDuration and mode of AMCSAMCS complication/sOutcomePatient 176 year old maleMI2012Re-do sternotomy and AVRSalvage peripheral VA ECMO due to postoperative pulmonary haemorrhageFemoral artery cannulation site pseudoaneurysmAliveCABGModerate LVSDMajor haemorrhage from cannulation siteNYHA I (No breathlessness of exertion, back to work)HypertensionHypercholestrolaemiaICD for VFCVAEuroSCORE = 27.48Patient 240 year old maleMV repair2014Re-do, Re-do sternotomy for type A aortic dissection: Bentall procedure.Salvage RVAD due to VF arrest and asystolic LV after CPBMajor haemorrhage and re-exploration in the operating theatreAliveMVRNYHA II (Breathless on exertion)Moderate LVSDMarfan's syndromeAFLogEuroSCORE = 29.18Patient 382 year old maleSevere LVSD2006MV Repair and CABG3 DaysCould not be weaned from ECMO with severe biVent failureDied in CTICUMIVA ECMO as unable to wean from CPBCOD: BiVent failureSevere TVDLogEuroSCORE = 17.45Patient 472 year old FemaleGood LV function2011AVR9 DaysSeptic shockDied in CTICUModerate MRVA ECMO as unable to come off CPBPeripheral ischaemiaCOD: Septic shockEuroSCORE = 12.11Patient 571 year old maleUrgent/Emergency Surgery2011CABGx3 and AVR2 DaysECMO cannulation site bleeding and haematoma exploredDied in CTICUPeripheral VA ECMO as unable to come off CPBRenal failure^a^COD: Shock (unknown cause)MI (\< 90 days)Severe LVSDSevere TVDAnaemiaLogEuroSCORE = 26.35Patient 683 year old femaleUrgent/Emergency Surgery2012MVR and CABG ×1\< 1 DayNoneDied in CTICUPeripheral VA ECMO as unable to come off bypass and awaited family to see patient last timeCOD: BiVent failureMI (\< 90 days)Severe LVSDAcute severe MRCardiogenic shockLogEuroSCORE = 73.26Patient 770 year old maleMI2013Re-do sternotomy and AVR33 DaysMajor CVADied in HDUCABGVA ECMO. Successfully weaned from ECMOCOD: severe Respiratory failureCVAHypertensionHypercholestrolaemiaGood LVLogEuroSCORE = 14.31Patient 872 year old maleModerate LVSD2013Re-do sternotomy and AVR\< 1 DayECMO cannulation femoral artery dissectionDied in CTICUCABGAtrial flutterVA ECMO after iatrogenic aortic dissection during Femoral cannulation for bypassMajor haemorrhageCOD: Major CVAHypertensionLogEuroSCORE = 13.09Major CVAPatient 951 year old maleModerate LVSD2013Re-suspension of Aortic valve and repair of type A aortic dissection1 DayMajor cannulation site haemorrhageDied in CTICULogEuroSCORE = 13.13Peripheral VA ECMOCOD: Haemorrahgic shock and BiVent failurePatient 1034 year old femaleGood LV2014IVC Leiomyosarcoma resection3 DaysNoneDied in CTICULogEuroSCORE = 2.08VA ECMOCOD: BiVent failure from acute MIPatient 1165 year old maleUrgent surgery2013CABG2 DaysRenal failure^a^Died in CTICUACS (Unstable angina)Salvage VA ECMOHepatic failureCOD: MODSLogEuroSCORE = 4.55Pulmonary oedemaPatient 1271 year old malePeripheral vasculopath2015CABG3 DaysMajor haemorrhage: Re-opening for bleeding ×4Died in CTICULogEuroSCORE = 3.67VA ECMO as unable to wean from CPBPeripheral leg ischaemiaCOD: biventricular failure and septic shockPatient 1349 year old maleEmergency Surgery1997CABGVA ECMONote recordedAlive (Died 2004) NYHA IIPVDIntra-operative MILogEuroSCORE = 5.69Patient 1469 year old maleActive IE2004MVR and CABG for mitral valve IEVA ECMOCVA and seizures Renal failure^a^Alive NYHA IIEmergency surgeryModerate LVSDLogEuroSCORE = 21.73Patient 1541 year old femaleEmergency surgery2005Aortic transection and diaphragmatic ruptureVA ECMONot recordedAlive NYHA IGood LVLogEuroSCORE = 25.50Patient 1659 year old maleMI (\< 90 days)2006Type A aortic dissection2 DaysNot recordedDied COD: Bivent failureSevere LVSDPeripheral VA ECMO as unable to come off bypassEmergency surgeryLogEuroSCORE = 33.90Abbreviations: *ACS* acute coronary syndrome, *AF* atrial fibrillation, *AMCS* advanced mechanical circulatory support, *AVR* aortic valve replacement, *CABG* coronary artery bypass grafting surgery, *CPB* cardiopulmonary bypass, *COD* cause of death, *BiVent failure* biventricular failure, *MVR* mitral valve replacement, *IE* infective endocarditis, *CVA* cerebrovascular accident, *IVC*, inferior vena-cava, *NYHA* New York Heart Association, *CTICU* cardiothoracic intensive care unit, *HDU* high dependency unit, implantable cardioverter defibrillator, *MI* myocardial infarction, *LVSD* left ventricular systolic dysfunction, *TVD* triple vessel coronary artery disease, *LV* left ventricular, *MR* mitral regurgitation, *PVD* peripheral vascular disease, *MODS* multi-organ dysfunction syndrome, *VF* ventricular fibrillation, *VAD* ventricular assist device, *VA* veno-arterial;^a^All patients with renal failure required renal replacement therapyFig. 1Illustrates the number of complications in our cohort

Most common cause of death (COD) was refractory biventricular failure (37.5 %, Fig. [2](#Fig2){ref-type="fig"}), in which group of patients, AMCS was withdrawn. One patient died due to combination of biventricular failure and haemorrhagic shock whilst on VA ECMO. Thirty-day survival was 37.5 % (Fig. [3](#Fig3){ref-type="fig"}). Our survival rate to hospital discharge was 31.2 %. Upon reviewing the consultant cardiologist follow-up clinic letters on the TrakCare^R^ database, all survivors who were discharged home were alive at 24 months and had NYHA class I-II functional status on follow-up.Fig. 2Illustrates the cause of death in our cohortFig. 3Kaplan-Meier curve of survival. FU: follow up (months), Cum Survival: cumulative survival

Advanced age, the emergent nature of surgery, pre-existing, preoperative severe left ventricular impairment were identified as possible factors leading to an adverse outcome. These findings however are limited due to the small number of subjects and the retrospective nature of the study.

Discussion & review of the literature {#Sec4}
=====================================

AMCS have been in evolution for almost 50 years. AMCS devices developed in parallel with the cardiopulmonary bypass (CPB) machine by John Gibbon in 1953 \[[@CR21], [@CR22]\]. Soon after its inception, the CPB machine was being used to salvage patients following "failed" cardiac surgery. In 1966, Michael DeBakey used the first LVAD to support a patient who was in refractory PCCS \[[@CR21]\]. After the first heart transplantation by Christiaan Barnard in 1967 and widespread acceptance of transplantation, AMCS devices have been regularly used to sustain those patients in refractory PCCS to allow time for decision for further management with implantable devices or heart transplantation \[[@CR21]\].

There are two forms of ECMO; veno-venous (VV) which is usually utilized to support isolated respiratory failure and veno-arterial (VA) ECMO used to support cardiac, respiratory or mixed cardiorespiratory failure. Both types of ECMO can be applied centrally and peripherally \[[@CR23], [@CR24]\]. There are two types of VADs. Short-term, percutaneous VADs, which can be inserted in the catheter laboratory, serve as a temporizing measure to stabilize patients in acute cardiogenic shock. More long-term, surgically-implanted VADs are designed to increase patient's life span and/or bridge patients to transplantation \[[@CR15]\]. VADs can be used to support the failing right ventricle, left ventricle or both. According to the UK VAD registry, scarcity of donor hearts has stimulated consideration of implantable AMCS devices for more prolonged circulatory support \[[@CR20]\]. Recent studies have demonstrated that modern continuous flow AMCS devices such as CentriMag^R^ pumps with magnetically levitated rotors and more effective modern oxygenators, can be more easily implanted, leading to much better survival in patients with post-cardiotomy cardiogenic shock in the recent years \[[@CR25]--[@CR27]\].

In our literature search we identified 15 major articles. In the largest cohort, Hernandez et al. \[[@CR3]\] collated data from 5,735 patients who underwent salvage VAD support for refractory PCCS. They reported 54.1 % survival rate to hospital discharge. They concluded that VAD is a valuable, life-saving therapeutic manoeuvre. Rastan et al. \[[@CR5]\] performed ECMO support in 516 patients with refractory PCCS. A total of 24.8 % of patients survived to discharge to the community. However, after 5 years 13.7 % were alive and 17.4 % of patients suffered severe morbidity \[[@CR5]\]. In another large cohort of 219 patients Doll et al. \[[@CR28]\] reported 24.8 % survival to discharge and 16.9 % 5-year survival for their cohort of refractory PCCS patients who had received salvage ECMO support. Hsu et al \[[@CR12]\] reported a cohort of 51 patients who had undergone cardiac surgery and suffered refractory PCCS requiring ECMO circulatory support. The 30-day, 3-month and 1-year mortality rates were 49, 65 and 71 % respectively. Mehta et al. \[[@CR13]\] reported a large cohort of 1,279 patients who had undergone VAD for circulatory support for refractory PCCS. They claimed that 584 (45.7 %) patients were successfully weaned from VAD and 323 (25.3 %) patients survived to discharge from the hospital. In a small cohort of 12 patients with refractory PCCS, DeRose et al. \[[@CR2]\] reported that 9 patients (75 %) survived to discharge from the hospital with LVAD implantation, 8 (67 %) survived to transplantation and 1 (8 %) successfully underwent explanation of LVAD not requiring transplantation. However, they reported 42 % rate of LVAD related infective complications.

With respect to longer term outcomes; a study by Ko et al. \[[@CR11]\] reported a cohort of 76 patients undergoing ECMO support for refractory PCCS. They reported that, although 46 patients (60.5 %) were successfully weaned from ECMO, 20 (26.3 %) survived to discharge. However all survivors were reported to be of New York Heart Association (NYHA) I and II functional status on 32 +/- 22 month follow-up. This quality of life finding is in keeping with the findings in our cohort. Pennington et al. \[[@CR17]\] reported refractory PCCS support with VAD with 37 % survival to hospital discharge. They reported that all survivors were "leading active lives". In 72.7 % of survivors ejection fraction had normalized on follow-up echocardiogram. AMCS devices also have disadvantages. They are currently not funded within the cardiac surgery tariff and are quite costly \[[@CR9], [@CR19], [@CR20]\]. According to a study conducted at the University Hospital of South Manchester \[[@CR9]\] (an NHS institution), the cost of capital equipment, device maintenance and single-use elements (e.g. tubing) of the CentriMag^R^ device is £3542. The total per patient cost of VAD and ECMO were reported as £15 669 and £8616 respectively. However the costs associated with the device and the ICU stay may vary substantially depending on the duration of AMCS. The cost of implantable VAD per patient receiving a device is £173,841 or US\$316,078. The most costly aspect is implantation of the device (£63,830, US\$116,056) and the initial hospital stay in the ITU and ward totals as much as £14,500 or US\$26,364 \[[@CR29]\]. A clinical trial indicated the cost of quality adjusted life year for ECMO in the UK to be £19,252 \[[@CR30]\]. Also there are reports \[[@CR1], [@CR2], [@CR11], [@CR16]--[@CR18]\] of serious device-related complications including: bleeding, thrombus formation and embolization, cerebrovascular accidents, device infection, limb ischaemia and multi-organ dysfunction syndrome/failure. However, there is evidence that on-the-table, early implantation of AMCS devices, prior to leaving the operating theatre from the initial operation, substantially improves survival as compared to late implantation out-with the operating theatre \[[@CR6], [@CR26]\]. Given the reported survival rates and the extent of resources involved, we recommend that each case should be assessed in its own individual merit. Involvement of a cardiac surgeon, other than the surgeon involved in the initial operation, the clinical director of the department of cardiac surgery, as well as involving the perfusionist and the on-call anaesthetist in the decision making process is imperative in gaining optimal outcomes for patients undergoing AMCS for refractory PCCS while optimising the cost-benefit equation.

Conclusion {#Sec5}
==========

AMCS devices can be used to salvage some patients with refractory PCCS who would otherwise have not survived. However, ACMS are associated with high rates of severe, systemic and device-related complications as well being costly. We recommend team approach to decision-making and early application of AMCS to the few carefully selected patients with refractory PCCS in order to optimise the cost-benefit equation. Our results reflect findings from previous studies. Our study showed survivors enjoyed a reasonable quality of life.
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